Futura Medical Share Discussion Threads

[petroc] 19/7/2022 23:23

Sometimes I actually feel sorry for LiarBO. Partly because of his investment naivety when he invested more than he could afford to lose, obviously, and also when he decided that he could sink FUM with his constant and unremitting stock bashing. Two very ridiculous decisions which have have cost him his happiness for the last five years. What a sorry loser he is! (Actually I lied about feeling sorry. Bwahahahaha!)

[petroc] 19/7/2022 16:11

There is nothing too boring that LiarBO won't copy/paste to keep his comments at the top of the board. That's his downfall really - everyone can see he has absolutely nothing to say except old rubbish. It's high time ADVFN took control of this situation. Why the hell would they want LiarBO to drag this board into the gutter like this? Surely the fact that he's paid them more than a grand in subscriptions over the years isn't worth having their name dragged through the mud by hosting this anti-FUM propaganda? He's broken the rules so many times they've had ample opportunity to ban him, like LSE did when they realised he was polluting their board and breaking all the rules. That's why if you want a balanced chat about FUM and MED3000, then LSE is the place to go.

[lbo] 19/7/2022 12:20

Just like in the EU and the CE Mark and the ASA in the UK. The FTC will also require adequately controlled studies to substantiate claims ‘it works’ any better then any placebo. The FTC will also not allow any claim it is ‘FDA approved’ as a De Novo device




CE-marking is no excuse for uncorroborated claims of efficacy. The successful CE certification of a medical device or remedy does not release companies from the obligation to prove the correctness of advertising statements.

the CE conformity assessment is neither an official approval procedure nor an administrative legal act. The so-called “notified bodies” which carry out conformity checks and award the CE-certificates are private companies. The tests carried out by these companies therefore rather amount to plausibility checks, which, moreover, only concern individual aspects, for example, of a production process. A product’s (alleged) therapeutic effectiveness is not (necessarily) examined.
In effect, the court enjoined the defendant from continuing the advertising of the product.








The de novo process allows FDA to establish new product classifications for low- to moderate-risk medical devices

Devices that are classified into class I or class II through a De Novo classification request



It is important to understand:

When a facility registers and lists its devices, the resulting entry in FDAs registration and listing database does not denote approval of that facility or its medical devices (FDA, 2021).

[petroc] 19/7/2022 12:05

Just when you thought LiarBO couldn't get any more boring, he posts that pile of manure. Again.

[lbo] 19/7/2022 10:22

The De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this De Novo authorization, the FDA is establishing criteria called special controls that define the requirements related to labeling and performance testing. When met, the special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness for devices of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device.The average length of time for clearance under the traditional 510(k) pathway is 177 dayshttps://www.pall.com/en/medical/blog/the-importance-of-fda-510k-cleared-product.htmla company must compare their product to one already cleared by the FDA and provide evidence that their product is substantially equivalent to the previously cleared (legally marketed) device. To be substantially equivalent, the product must meet criteria for the same intended use, have the same technology or (slightly) different technology but produces similar end results, and be safe and effective. Once pre-market clearance is received from the FDA the device can be distributed commercially immediately.

[petroc] 19/7/2022 09:59

I thought it would be just a matter of time before LiarBO got onto his favourite subjects, anal intercourse and condoms. Though quite why he likes to talk about condoms is beyond me, as he lost all his money when CSD500 failed to sell. Perhaps it helps to keep his bitterness stoked up, to motivate him into copy/pasting the same old drivel as often as possible in order to bash the stock. Sad knacker.

[lbo] 19/7/2022 08:28

Anyone can (if they believe there is a genuine market for a MED3000 in the real world can launch their own version of MED3000, based on the Voltaren alcohol and water vehicle gel. That is if MED3000 does manage to get registered as a De Novo medical device. Or they then just copy Dermasys which is off patent and still has no patent yet on its own for ED or just use something very similar based on Voltaren vehicle gel and get it registered via the 510k route.https://www.edisoninvestmentresearch.com/?ACT=18&ID=10479There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial productshttps://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-condom-specifically-indicated-anal-intercourseThe FDA reviewed the One Male Condom through the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this De Novo authorization, the FDA is establishing criteria called special controls that define the requirements related to labeling and performance testing. When met, the special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness for devices of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device.The average length of time for clearance under the traditional 510(k) pathway is 177 days,https://www.pall.com/en/medical/blog/the-importance-of-fda-510k-cleared-product.htmla company must compare their product to one already cleared by the FDA and provide evidence that their product is substantially equivalent to the previously cleared (legally marketed) device. To be substantially equivalent, the product must meet criteria for the same intended use, have the same technology or (slightly) different technology but produces similar end results, and be safe and effective. Once pre-market clearance is received from the FDA the device can be distributed commercially immediately.

[petroc] 18/7/2022 21:51

Thank you for repeating those posts again LiarBO. I thought you probably would and it added even more proof to what I said previously - that you are a scheming, lying, stock basher who is only here to post your anti-FUM propaganda.

[lbo] 18/7/2022 20:57

And yet more false claims

petroc - 20 Feb 2020 - 10:14:36 - 7278 of 12535

PDT, as Dermasys has been Futura's core product for several years, and upon which they base their marketing strategy, I very much doubt that it's easy to replicate faithfully or legally



GlaxoSmithKline unexpectedly handed back the development rights to Futuras erectile dysfunction gel. We are not going to progress on this particular compound for normal commercial reasons which we do not wish to go into, GSK said.



The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.


Dermasys on its own has no patent anymore. Even the Dermasys trademark predates by many years the umbrella patents covering MED2005 (Dermasys and GTN) and TPR100 (Dermasys and Diclofenac) which are all expiring soon also.

from Trinity in a previous note regarding the MED2005 patent:

˜long development period resulted in a material erosion of the patent life, with the original formulation patent expected to expire in 2025

Dermasys is even older so is off patent

2002 plus 20 years = 2022



The DermaSys(R) technology was originally developed by Futura for use in the Company's topical treatment for erectile dysfunction, MED2002





Under the terms of the agreement, Thornton & Ross will conduct the manufacturing scale-up of TPR100 and hold rights to manufacture, market and distribute the product in the UK for the lifetime of the product's patents, which run to at least 2028 in the UK

[lbo] 18/7/2022 20:53

Petroc the proven ramping Liar. The share price did not get to 90p in December 2019 or in 2021 even with his. multi-ID ramping all over the internet.https://seekingalpha.com/instablog/441189-mike-rabe/28602-15-ways-to-spot-stock-discussion-board-rampers1. The rampers post exorbitant stock price predictions.3. They attack those who disagree with their lofty predictions. They cannot back up their arguments with a rational discussion, so they resort to petty name calling and telling others who disagree with them that they are "full of it."4. You cannot have an intelligent discussion with these types. They will do whatever they can to discredit those who disagree with them by spreading false information. They are very often antagonistic.5. They post their predictions over and over and over desperately hoping to move the market. They never do, because what they say is insignificant to the market.petroc - 01 Dec 2019 - 11:12:08 - 6461 of 10529I'm sticking to the prediction I made last week - 92p, mid December.petroc - 27 Nov 2019 - 11:52:54 - 6439 of 1052992p, mid December.

[lbo] 18/7/2022 20:49

Petroc is a proven liar. He has posted false claims on ADVFN as 'FACTS'. And never gave any disclaimers until challenged that they were not actually facts as he had tried to claim at the time.http://uk.advfn.com/cmn/fbb/thread.php3?id=33313581&from=10569petroc - 09 Jan 2022 - 16:44:16 - 10345 of 10423Of course it workspetroc22 Jan '22 - 19:08 - 10569 of 10768What is not to love Eroxon /MED3000 - HERE ARE THE FACTShttps://www.asa.org.uk/rulings/pro-bono-bio-entrepreneur-ltd-a17-400871.htmlThe CAP Code required that objective claims, including medical claims for a CE-marked medical device, be backed by evidence,https://www.asa.org.uk/static/uploaded/f6d9a0c6-3e9b-475b-aa831a597de615ff.pdfWhat standards are applied to evidence? The position taken by the ASA is a tried and tested one which has developed over the course of many years. It reflects the opinion of the wider scientific and academic community, rather than judgements made solely by the ASA. There are many aspects that are taken into consideration when evidence is reviewed and each claim is judged on its merits alongside the evidence presented to support it. Evidence submitted for health claims should normally include at least one adequately controlled experimental human

[petroc] 18/7/2022 17:37

Difficult to believe that LiarBO was describing rampers and not himself when he said, 'They are not open minded. You cannot have an intelligent discussion with these types. They will do whatever they can to discredit those who disagree with them by spreading false information. They are very often antagonistic.' That is LiarBO in a nutshell. And btw, the information about LiarBO's stock bashing and constant reposting of anti-FUM propaganda is absolutely true, which you can see by just picking any one of his half dozen or so copy/pasted scripts.

[lbo] 16/7/2022 17:51

One slimy character in particular to be vigilant of is the omnipresent stock ramper. S/he can be found on almost every discussion board / forum and too many times investors can make bad buy decisions by following the ramper’s misguided advice.

They attack those who disagree with their lofty predictions. They cannot back up their arguments with a rational discussion, so they resort to petty name calling

They are not open minded. You cannot have an intelligent discussion with these types. They will do whatever they can to discredit those who disagree with them by spreading false information. They are very often antagonistic.



Recent research has shown that the placebo effect is not only similar for medical devices to medical trials; it is considerably larger – the effect of a sham device is almost three times that of an oral placebo.

This proves the case for the need of medical devices to be approved based on trials that compare them at first to sham devices.



A good number of men receiving a placebo in clinical trials for erectile dysfunction drugs experienced an improvement in their function, researchers said in a report published online March 20 in JAMA Network Open.

This placebo effect was most pronounced in men with post-traumatic stress disorder (PTSD), suggesting that for some men psychology is more important than physiology in dealing with erectile dysfunction, said lead researcher Alexander Stridh of the Karolinska Institute's department of clinical neuroscience, in Stockholm.

"The placebo response seems largely more important when the cause of [erectile dysfunction] is mainly due to psychogenic factors, as in post-traumatic stress disorder," Stridh said.

The studies showed that Viagra and its relatives had a strong effect helping men who had erectile dysfunction due to chronic illness.

"The studies included in this meta-analysis mainly were trials on men with [erectile dysfunction] due to cardiovascular disease, diabetes, etc.," Stridh said. "It is likely that there is a limit to how much the brain can influence erectile function when the problem is mainly dysfunctions in blood vessels or peripheral nerves."

But the researchers found that men in the placebo arm of these trials also experienced a small to moderate improvement of their erectile function. The placebo effect was notably stronger among men with PTSD.

"This paper highlights the importance of taking into account the underlying cause of [erectile dysfunction] in each individual, which could also help determine what the best treatment option would be," Stridh said. Some men might benefit more from psychotherapy, others with a pharmaceutical approach, he added.

"It is clear that Viagra and other [erectile dysfunction drugs] work very well in many cases, but we should not disregard the importance of psychological aspects of [erectile dysfunction], particularly in individuals who have no clear physiological causes for [the condition]," Stridh said.

Urologist Dr. Manish Vira said the researchers have a point.

"Given the significant improvement in symptoms with placebo among patients with PTSD, the study suggests that physicians should work to address some of the psychological stress factors prior to starting patients on medication for treatment," said Vira. He is vice chairman for urologic research at Northwell Health's Arthur Smith Institute for Urology in New Hyde Park, N.Y.

Stridh said the analysis also found that Viagra-like drugs don't work better than placebo for long-term recovery of erectile function after prostate cancer treatment, a common practice in some places that he added "seems to be questionable."

Although the results seem to indicate that some men would benefit more from counseling, Stridh cautioned that a perceived placebo effect might actually be natural fluctuations in symptom severity.

"Patients have a tendency to seek help when their symptoms are on the worse end and might be improved within a couple of weeks regardless of the treatment given," he said.

[petroc] 16/7/2022 15:22

So you're still pushing the line that ED is all in the head. The depths you sink to in order to bash the stock disgust me, LiarBO.

[lbo] 16/7/2022 15:09

This placebo effect was most pronounced in men with post-traumatic stress disorder (PTSD), suggesting that for some men psychology is more important than physiology in dealing with erectile dysfunction, said lead researcher Alexander Stridh of the Karolinska Institute's department of clinical neuroscience, in Stockholm.
"The placebo response seems largely more important when the cause of [erectile dysfunction] is mainly due to psychogenic factors, as in post-traumatic stress disorder," Stridh said.
For this analysis, his team pooled data from 63 studies involving more than 12,500 men.
The studies showed that Viagra and its relatives had a strong effect helping men who had erectile dysfunction due to chronic illness.
"The studies included in this meta-analysis mainly were trials on men with [erectile dysfunction] due to cardiovascular disease, diabetes, etc.," Stridh said. "It is likely that there is a limit to how much the brain can influence erectile function when the problem is mainly dysfunctions in blood vessels or peripheral nerves."
But the researchers found that men in the placebo arm of these trials also experienced a small to moderate improvement of their erectile function. The placebo effect was notably stronger among men with PTSD.
"This paper highlights the importance of taking into account the underlying cause of [erectile dysfunction] in each individual, which could also help determine what the best treatment option would be," Stridh said. Some men might benefit more from psychotherapy, others with a pharmaceutical approach, he added.